The direct and indirect costs associated with endometriosis: a systematic literature review
review
OA: bronze
CC0
⤵ 170 in-corpus citations
AI-generated summary
This systematic review found that endometriosis incurs substantial direct and indirect costs, with estimates varying widely by study methodology and country.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
STUDY QUESTION: What is the economic burden of endometriosis? SUMMARY ANSWER: The identified studies indicate that there is a significant economic burden associated with endometriosis, as observed by both direct and indirect costs. WHAT IS KNOWN ALREADY: Two previous systematic literature reviews suggested that there were considerable direct costs associated with endometriosis and there was a general lack of measurement of indirect costs. STUDY DESIGN, SIZE, DURATION: We performed a systematic literature review. MEDLINE and EMBASE databases from 2000 to 2013 were searched. The literature search was limited to human studies of patients with endometriosis. Papers in languages other than English were excluded. PARTICIPANTS/MATERIALS, SETTING, METHODS: Studies reporting direct or indirect costs among patients with endometriosis were considered for inclusion. Direct costs included inpatient, outpatient, surgery, drug and other healthcare service cost. Indirect costs were related to absenteeism and presenteeism (lost productivity at work). MAIN RESULTS AND THE ROLE OF CHANCE: After evaluating the 1396 articles in the search results, 12 primary studies that reported direct or indirect costs associated with endometriosis were identified and included in the data extraction. Three of the studies were conducted in the USA, one study each was conducted in Austria, Belgium, Brazil, Canada, Finland, Germany and Italy, and two studies included data from 10 countries. Significant variability was observed in the reviewed studies in methodology, including data source, cost components considered and study perspective. Estimates of total direct costs ranged from $1109 per patient per year in Canada to $12 118 per patient per year in the USA. Indirect costs of endometriosis ranged from $3314 per patient per year in Austria to $15 737 per patient per year in the USA. LIMITATIONS, REASONS FOR CAUTION: The studies identified in the systematic literature review varied greatly by study methodology as well as by country owing to different healthcare systems and costs of healthcare services, which contributed to large variations in the direct and indirect cost estimates. WIDER IMPLICATIONS OF THE FINDINGS: A majority of the studies we found were published after the periods covered in the prior systematic literature reviews, which provided substantial contributions to an understanding of the economic burden of endometriosis, especially in the area of indirect costs. The long-term burden of endometriosis following diagnosis is still under-studied, which is a concern given the chronic nature of the disease and the substantial recurrence of endometriosis symptoms. STUDY FUNDING/COMPETING INTERESTS: This study was funded by AbbVie, which also develops the oral GnRH antagonist elagolix (in collaboration with Neurocrine Biosciences) for the management of endometriosis and uterine fibroids. A.M.S. is an employee of AbbVie and currently owns AbbVie stocks. H.Y., E.X.D. and C.K. are employees of Analysis Group, Inc., which has received consultancy fees from AbbVie. C.W. is a Clinical Professor at the Department Obstetrics and Gynecology at Georgetown University in Washington, DC, USA and has served in a consulting role to AbbVie for this project.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (35)
- Actuarial Analysis of Private Payer Administrative Claims Data for Women With Endometriosis via openalex
- Costs of endometriosis in Austria: a survey of direct and indirect costs via openalex
- Costs of in-patient treatment for endometriosis in Germany 2006: an analysis based on the G-DRG-Coding via openalex
- Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences via openalex
- Economic burden of endometriosis via openalex
- Endometriosis via openalex
- Endometriosis via openalex
- Endometriosis: cost estimates and methodological perspective via openalex
- Endometriosis: Treatment Strategies via openalex
- Evaluation and management of women with endometriosis via openalex
- Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases via openalex
- Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries via openalex
- Laparoscopic surgery for subfertility associated with endometriosis via openalex
- Laparoscopic surgery for subfertility associated with endometriosis via openalex
- Non-health-care costs associated with endometriosis via openalex
- Reducing low-value care in endometriosis between limited evidence and unresolved issues: a proposal via openalex
- Surgical procedures and their cost estimates among women with newly diagnosed endometriosis: a US database study via openalex
- The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres via openalex
- The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres via openalex
- W2157853773 via openalex
- W2114410175 via openalex
- W2082347947 via openalex
- W2041104023 via openalex
- W2163315477 via openalex
- W2165936652 via openalex
- W2206304062 via openalex
- W2015868420 via openalex
- W2003596169 via openalex
- W2404796697 via openalex
- W2405203370 via openalex
- W2417146555 via openalex
- W6713401460 via openalex
- W3124564277 via openalex
- W6713296015 via openalex
- W2154785975 via openalex
Cited by (50)
- Financial Toxicity in Women with Endometriosis: Psychometric Validation of the Polish COST-FACIT with Analysis of Demographic and Clinical Factors 2026
- Aberrant mitochondria in endometriosis: From pathogenic mechanisms to therapeutic opportunities 2026
- Minimizing Repeat Surgeries for Endometriomas: The Impact of Surgical Intervention by Minimally Invasive Gynecologic Surgeons 2026
- Experiences towards hormonal treatments: a qualitative study among endometriosis patients and healthcare professionals 2026
- THE INVISIBLE BURDEN OF ENDOMETRIOSIS: A REVIEW OF DIAGNOSTIC, TREATMENT, AND HEALTH POLICY CHALLENGES 2026
- A Clinical Overview of Endometriosis 2025
- Endometriosis and Endometriosis-Associated Tumors 2025
- Endometriosis management in a low/middle income country – Integration of a multidisciplinary medical team and patient social support group 2025
- Global, regional, and national burden of endometriosis among women of childbearing age from 1990 to 2021: a cross-sectional analysis from the 2021 global burden of disease study 2025
- Prise en charge ostéopathique des douleurs pelviennes chroniques de la femme. Série de cas traités 2025
- Virtual reality-based pain control in endometriosis: a questionnaire-based pilot study of applications for relaxation and physical activity 2025
- Endometriosis and autoimmunity 2025
- Comprehensive Review of Endometriosis Care 2025
- Medical expenditures associated with abdominal and pelvic pain in the United States, 2017-2021 2025
- Inverse association between dietary antioxidant intake and endometriosis among US women: A cross-sectional NHANES study 2025
- Endometriosis 2025
- Menstrual health and endometriosis: costs incurred by women, health systems and society 2025
- Health-related decision-making experiences of people with endometriosis: a qualitative analysis 2025
- Safety and efficacy of subcutaneous injection with HMI-115 versus placebo in endometriosis-associated pain in premenopausal women: a multicentre, double-blind, randomised, proof-of-concept phase 2 trial 2025
- Sensibiliser les professionnels de santé à l’endométriose. Conception d’une brochure d’information à destination des masseurs-kinésithérapeutes 2025
- Evaluation of the Epidemiological Disease Burden and Nationwide Cost of Endometriosis in Hungary 2024
- Endometriosis: A Narrative Review 2024
- Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study 2024
- Health and socioeconomic well-being of women with endometriosis and provoked vestibulodynia: Longitudinal insights from Swedish registry data 2024
- Virtual reality-based pain control in endometriosis: a questionnaire-based pilot study of applications for relaxation and physical activity (Preprint) 2024
- Additional file 1 of The coagulation status in women of endometriosis with stage IV 2024
- High-fat diets promote peritoneal inflammation and augment endometriosis-associated abdominal hyperalgesia 2024
- A systematic review of epigenetics of endometriosis 2024
- The coagulation status in women of endometriosis with stage IV 2024
- Effect of Dietary Interventions on Endometriosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 2024
- Mendelian randomization Identifies RSPO3 in Serum as a Potential Target for Endometriosis 2024
- Additional file 1 of The coagulation status in women of endometriosis with stage IV 2024
- Perspectives de la qualité de vie avec l’endométriose 2024
- Additional file 1 of Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study 2024
- Additional file 1 of Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study 2024
- Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3) 2024
- “Ladies first”: a plea for prioritizing women’s inclusion in the research and health care agenda 2024
- Associations between stigma and depression among college-attending women with endometriosis symptoms 2024
- Identification and validation of an endoplasmic-reticulum-stress-related gene signature as an effective diagnostic marker of endometriosis 2024
- Endometriosis and Endometriosis-Associated Tumors 2024
- MRI of endometriosis 2023
- Understanding Psychological Symptoms of Endometriosis from a Research Domain Criteria Perspective 2023
- Spheroids as a model for endometriotic lesions 2023
- Gastroenterologist Primer: Endometriosis for Gastroenterologists 2023
- Validation of the Canadian Institute for Health Information Diagnostic Codes for Benign Gynaecologic Surgery 2023
- A Novel Classification of Endometriosis Based on Clusters of Comorbidities 2023
- Current endometriosis care and opportunities for improvement 2023
- "Functional Outcomes and Quality of Life After Laparoscopic Nerve-Sparing Radical Treatment of Parametrial Deep Infiltrating Endometriosis" 2023
- Assessment of a Digital Symptom Checker Tool's Accuracy in Suggesting Reproductive Health Conditions: Clinical Vignettes Study 2023
- Acceptability of using the Raising Awareness Tool for Endometriosis (<scp>RATE</scp>) in general practice: a mixed methods pilot study 2023
Source provenance
- europepmc
- last seen: 2026-06-12T06:13:51.797165+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:21:13.485820+00:00
License: CC0
· commercial use OK